Prevalence of HCV Infection in Nongastric Marginal Zone B-cell Lymphoma of MALT
Overview
Authors
Affiliations
Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome.
Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus.
Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.
Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.
Zhang Q, Yan W, Li H, Peng H Curr Treat Options Oncol. 2025; 26(2):142-155.
PMID: 39891871 DOI: 10.1007/s11864-025-01293-w.
Miyake K, Hirasawa K, Nishimura H, Tsukahara K World J Clin Cases. 2024; 12(31):6506-6512.
PMID: 39507115 PMC: 11438690. DOI: 10.12998/wjcc.v12.i31.6506.
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F J Clin Oncol. 2022; 40(35):4060-4070.
PMID: 35714311 PMC: 9746784. DOI: 10.1200/JCO.22.00668.
Zhang M, Gao F, Peng L, Shen L, Zhao P, Ni B Cancer Cell Int. 2021; 21(1):524.
PMID: 34627251 PMC: 8502277. DOI: 10.1186/s12935-021-02230-1.
Litescu M, Baboi I, Paverman L, Vrabie C, Iordache N, Coman I Rom J Morphol Embryol. 2021; 61(3):929-934.
PMID: 33817736 PMC: 8112798. DOI: 10.47162/RJME.61.3.33.